€0.30
Your prediction
Financial data and news for Tempramed Technologies Ltd.
sharewise wants to provide you with the best news and tools for Tempramed Technologies Ltd., so we directly link to the best financial data sources.
Financials
News
TempraMed Expands Institutional Healthcare Network with Meuhedet Health Services, a Leading HMO in Israel, Covering Over 1 million Lives
Acceptance of TempraMed’s products by Meuhedet Health Services strengthens TempraMed's B2B institutional commercialization strategy as the Company advances reimbursement initiatives and
TempraMed Signs LOI for Exclusive Distribution in Kuwait, Expanding Presence in High-Growth Gulf Region Healthcare Market
Highlights
- TempraMed signs non-binding LOI for exclusive distribution in Kuwait with Elegir Trading
- Kuwait represents a high-value market with significant demand for
TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels
Integration into McKesson’s Medical-Surgical Solutions marketplace serving a nationwide customer base
Toronto, ON – June 30, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY)
TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product
Another major milestone in its continuous global IP strategy, advancing protection of VIVI Cap Smart across international markets
Highlights
- Granted Patent covers the design
TempraMed Partners with Super-Pharm, Israel’s Leading Pharmacy Chain to Commence a National Product Roll Out Strategy
Super-Pharm operates nationwide, serving millions of consumers annually
Vancouver, BC - February 10, 2026 - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company
TempraMed Launches National Brick and Mortar Pharmacy Roll Out, Shipping Products to Maccabi Pharmacies Across Israel
Key Commercialization Milestone in Retail Pharmacy Network that Serves Over 2.8 Million Insured Members
Vancouver, BC – February 6, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY)
TempraMed Enters Strategic Media Partnership with Dr. Phil’s Envoy Media, Validating Product Portfolio and Accelerating Market Adoption Across the United States
Access to an audience of over 19 million individuals monthly will expand national exposure, and supports scalable demand generation across B2C and B2B channels for TempraMed’s full product